How does NAD+ work in the body?

NAD+ (nicotinamide adenine dinucleotide) does two molecular jobs at once. First, it is a redox coenzyme: it carries pairs of electrons between reactions as the NAD+/NADH couple, which is central to extracting energy from food and feeding mitochondrial energy production. In this role NAD+ is recycled, not used up. Second, it is a cosubstrate that signalling enzymes consume — they cleave NAD+ to power chemical modifications of proteins. Both roles draw on the same intracellular NAD+ pool, which is why cells continuously resynthesise NAD+ to keep the supply balanced. NAD+ is a coenzyme found in every cell, not a medicine.

What are sirtuins and how do they relate to NAD+?

Sirtuins are a family of NAD+-dependent enzymes called deacylases — they remove acyl groups, such as acetyl groups, from proteins, and they cannot do this without consuming a molecule of NAD+ in the process. Because their activity depends directly on how much NAD+ is available, sirtuins act as sensors that link a cell’s metabolic state to the regulation of stress responses and metabolism. This coupling is why sirtuins sit at the centre of laboratory longevity biology. Importantly, the lifespan effects tied to sirtuins come largely from simple model organisms; whether the same mechanism produces meaningful outcomes in humans remains an open research question, not an established result.

Why does NAD+ decline with age?

Tissue NAD+ measured across model organisms — yeast, worms, flies, and mice — falls with age, and the same direction has been reported in smaller human datasets. The proposed mechanism is a tug-of-war between supply and demand. On the demand side, the enzyme CD38, a major NAD+ consumer, rises with age and draws down the pool, while PARP enzymes consume more NAD+ as DNA damage accumulates. Because sirtuins, PARPs, and CD38 all draw on the same finite NAD+ supply, heavy use strains the whole system. The net result is lower tissue NAD+. This decline is associated with ageing biology in laboratory studies, but is not proven to cause any specific human disease.

What is CD38’s role in NAD+?

CD38 is one of the major NAD+-consuming enzymes in the body, and it matters mostly for its sheer appetite for the molecule. Its expression and activity rise with age across tissues, so as CD38 climbs it draws down the available NAD+ pool — making increased CD38 activity one of the proposed drivers of the age-related NAD+ decline seen in older animals. CD38 also does more than consume NAD+: when it cleaves NAD+ and related molecules, it generates the calcium-mobilising second messengers cyclic ADP-ribose (cADPR) and NAADP. That ties the NAD+ pool directly into calcium signalling, one of the most universal control systems in the cell.

Does boosting NAD+ slow aging in humans?

The honest answer is that this is not established. The molecular biology is solid — NAD+ falls with age, and the enzymes that consume it sit at the centre of metabolic, DNA-repair, and calcium-signalling pathways. But almost all of the evidence that restoring NAD+ produces benefit comes from model organisms such as yeast, worms, flies, and mice, where raising NAD+ improves laboratory measures of healthspan. Those findings are the rationale for the human trials now underway, not a clinical result. NAD+ research is genuinely promising as a target, but that is a different statement from saying it slows ageing or treats any condition in people. NAD+ is a coenzyme, not a medicine, and this is not medical advice.

Research · NAD+ cluster

NAD+ mechanism research — redox, sirtuins, PARPs, CD38

Creator: Wellness Labs Editorial
Published: 2026-06-11
Keywords: NAD+ mechanism, NAD+ mechanism, NAD+ mechanism of action, NAD sirtuins, NAD CD38, NAD DNA repair, why NAD declines with age, NAD redox cosubstrate, cADPR NAADP second messengers

Wellness Labs Editorial·11 June 2026·8 min read

Medically reviewed by

Wellness Labs Research Team · Research and Editorial

Last reviewed 1 June 2026

The NAD+ parent guide answers what the molecule is and what the supplement category looks like. This spoke goes a level deeper into the molecular biology researchers actually argue about: NAD+ is not one thing doing one job. It is a single coenzyme that lives a double life — quietly shuttling electrons through energy metabolism, and at the same time being consumed as a raw material by a set of enzymes that signal stress, repair DNA, and remodel calcium. Understanding that dual identity is the key to understanding everything else in the NAD+ literature.

TL;DR

NAD+ (nicotinamide adenine dinucleotide) has two distinct molecular jobs. First, as a redox coenzyme it carries electrons between reactions — the NAD+/NADH couple is central to extracting energy from food — and in this role it is recycled, not used up. Second, it is a cosubstrate that is consumed by three NAD+-degrading enzyme families: sirtuins (NAD+-dependent deacylases tied to metabolic and longevity signalling), PARPs (poly-ADP-ribose polymerases involved in DNA repair), and CD38 (a major NAD+ consumer that rises with age). Because these enzymes break NAD+ apart, they also generate the calcium-signalling second messengers cADPR and NAADP. Tissue NAD+ measured across model organisms declines with age, and that decline is associated with ageing biology in laboratory studies. Crucially, the benefits of restoring NAD+ come largely from yeast, worm, fly, and mouse models — they are not established human clinical outcomes. NAD+ is a coenzyme, not a medicine, and nothing here is medical advice. See the parent overview for the supplement category.

NAD+’s two jobs — coenzyme and cosubstrate

Most people first meet NAD+ as a redox coenzyme, and that is its oldest and most fundamental role. In this job NAD+ accepts a pair of electrons (becoming NADH) in one reaction and donates them (returning to NAD+) in another. That NAD+/NADH cycling is the chemistry that lets cells extract energy from glucose and fat and feed it into mitochondrial ATP production. The defining feature of this role is that NAD+ is regenerated — it is a catalyst, used over and over, neither created nor destroyed by the reactions it enables [1].

The second job is what makes NAD+ biology interesting beyond metabolism, and it works in the opposite way. A set of enzymes does not merely borrow NAD+ as an electron carrier — they cleave it, splitting the molecule and consuming it as a substrate to power a chemical modification. In this role NAD+ is genuinely used up, which means the cell must continuously resynthesise it (mainly through the salvage pathway). Reviews of NAD+ homeostasis describe this as an evolutionary shift in how biology came to use the molecule: from a humble metabolic cofactor to a consumed cosubstrate for an entire class of signalling reactions [3].

The same molecule is recycled as an electron carrier and destroyed as a signalling substrate. That tension — recycled here, consumed there — is why NAD+ supply is something cells have to actively defend.

This dual identity is why so much NAD+ research converges on a single question: how much NAD+ is available? The redox role and the consuming enzymes draw on the same intracellular pool. When demand from the consuming enzymes rises — or synthesis falls — the balance shifts. The three enzyme families below are the consumers.

Sirtuins — NAD+-dependent signalling enzymes

Sirtuins are the most-discussed of the NAD+-consuming families. They are NAD+-dependent deacylases: they remove acyl groups (most familiarly acetyl groups) from proteins, and they cannot perform that reaction without consuming a molecule of NAD+ in the process. Because their activity is tied directly to NAD+ availability, sirtuins act as sensors that couple a cell’s metabolic state to downstream regulation of stress responses and metabolism [1].

That coupling is the reason sirtuins sit at the centre of laboratory longevity biology. The logic is mechanistic: NAD+ levels reflect energy status, sirtuins read NAD+ levels, and sirtuins in turn adjust the programmes that govern metabolic and stress adaptation. Reviews of NAD+ homeostasis specifically trace the molecule’s evolution into a cosubstrate for the sirtuins as a defining development in cellular signalling [3]. Whether this mechanism translates into the lifespan effects observed in simple model organisms remains a research question, not an established human outcome.

PARPs and DNA repair

The second consuming family is the PARPs — poly-ADP-ribose polymerases. When DNA is damaged, PARP enzymes are recruited to the break and respond by building chains of ADP-ribose onto target proteins, a modification that helps organise the DNA-repair machinery. Each unit added to those chains is taken from a molecule of NAD+, so an episode of DNA damage can draw heavily on the cellular NAD+ pool [1].

This creates a direct, well-documented link between genome maintenance and NAD+ economics. Reviews of NAD+ metabolism in ageing describe how PARP activity, sirtuin activity, and CD38 activity all compete for the same finite NAD+ supply, tying together DNA repair, cellular senescence, and the gradual decline of NAD+ with age into one interconnected picture [2]. When DNA-damage burden is high, PARP demand for NAD+ rises — and the metabolic and signalling roles that depend on the same pool feel the strain.

CD38 and the age-related decline

The third consumer, CD38, matters less for any single elegant function and more for sheer appetite. CD38 is a major NAD+-consuming enzyme, and — importantly — its expression and activity rise with age across tissues. As CD38 activity climbs, it draws down the available NAD+ pool, and reviews of NAD+ metabolism in ageing identify increased CD38 activity as one of the proposed drivers of the tissue NAD+ decline seen in older animals [2].

That decline is one of the more reproducible observations in the field. Tissue NAD+ measured across model organisms — yeast, worms, flies, and mice — falls with age, and the same direction of change has been reported in the smaller human datasets available [3]. The mechanistic picture is a tug-of-war: synthesis on one side; rising consumption (CD38 especially, plus PARP demand from accumulating DNA damage) on the other. The age-related drop is the net result.

It is worth being precise about what this decline means and does not mean. The observation — NAD+ falls with age — is well supported. The link between that fall and ageing-associated disease, reported in mechanistic and preclinical work, is an association studied largely in cells and animals [2]. It is not evidence that lower NAD+ causes any specific human disease, nor that raising NAD+ treats one.

Second messengers — cADPR and NAADP

There is a fourth consequence of NAD+ being a consumed substrate, and it closes the loop with cell signalling. When certain NAD+-dependent enzymes (CD38 prominent among them) cleave NAD+ and its relatives, they do not just degrade the molecule — they generate small signalling products. Two of these are the calcium-mobilising second messengers cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) [4].

This matters because it reframes the consuming enzymes as more than NAD+ drains. By producing cADPR and NAADP, they tie the NAD+ pool directly into calcium signalling — one of the most universal control systems in the cell. So NAD+ ends up wired into three layers at once: the redox metabolism that recycles it, the protein-modifying signalling (sirtuins, PARPs) that consumes it, and the calcium second-messenger system that its breakdown products feed. A single coenzyme, three layers of biology.

What this does — and doesn’t — tell us about humans

The molecular biology above is, for the most part, solid. The redox role is textbook biochemistry. The three consuming families and their reactions are well characterised. The cADPR / NAADP messenger pathway is established. The age-related NAD+ decline is reproducible across model organisms. Where the honesty has to come in is the next step — the leap from mechanism to human benefit.

Almost all of the evidence that restoring NAD+ produces benefit comes from model organisms. Reviews of NAD+ metabolism in ageing describe how raising NAD+ improves measures of healthspan and disease markers in laboratory models, and note those findings as the rationale for the human trials now underway [2]. That is a research rationale, not a clinical result. NAD+ biology is genuinely promising as a research target — and that is a categorically different statement from saying it does anything to ageing or disease in people.

The mechanism is real. The model-organism benefits are real. The human clinical outcomes are not yet established — and no honest reading of the literature claims otherwise.

So the careful framing: NAD+ falls with age (observed), and the enzymes that consume it sit at the centre of metabolic, DNA-repair, and calcium-signalling biology (characterised). Whether topping NAD+ back up changes how humans age is the open question the field is actively trying to answer. NAD+ is a coenzyme, not an approved medicine; this article is research education, not medical advice, and nothing here describes treating, preventing, or reversing any condition.

For the supplement category, the precursor question, and the UAE market read the NAD+ in the UAE parent guide. To compare the molecules people actually buy — and why oral NAD+ itself is poorly absorbed — see NAD+ vs NMN vs NR. For where the human evidence actually stands today, see NAD+ human trials evidence. Overview: the research compounds in the UAE hub, and the NAD+ 100 mg research-consultation page.

Frequently asked questions

How does NAD+ work in the body?: NAD+ (nicotinamide adenine dinucleotide) does two molecular jobs at once. First, it is a redox coenzyme: it carries pairs of electrons between reactions as the NAD+/NADH couple, which is central to extracting energy from food and feeding mitochondrial energy production. In this role NAD+ is recycled, not used up. Second, it is a cosubstrate that signalling enzymes consume — they cleave NAD+ to power chemical modifications of proteins. Both roles draw on the same intracellular NAD+ pool, which is why cells continuously resynthesise NAD+ to keep the supply balanced. NAD+ is a coenzyme found in every cell, not a medicine.
What are sirtuins and how do they relate to NAD+?: Sirtuins are a family of NAD+-dependent enzymes called deacylases — they remove acyl groups, such as acetyl groups, from proteins, and they cannot do this without consuming a molecule of NAD+ in the process. Because their activity depends directly on how much NAD+ is available, sirtuins act as sensors that link a cell’s metabolic state to the regulation of stress responses and metabolism. This coupling is why sirtuins sit at the centre of laboratory longevity biology. Importantly, the lifespan effects tied to sirtuins come largely from simple model organisms; whether the same mechanism produces meaningful outcomes in humans remains an open research question, not an established result.
Why does NAD+ decline with age?: Tissue NAD+ measured across model organisms — yeast, worms, flies, and mice — falls with age, and the same direction has been reported in smaller human datasets. The proposed mechanism is a tug-of-war between supply and demand. On the demand side, the enzyme CD38, a major NAD+ consumer, rises with age and draws down the pool, while PARP enzymes consume more NAD+ as DNA damage accumulates. Because sirtuins, PARPs, and CD38 all draw on the same finite NAD+ supply, heavy use strains the whole system. The net result is lower tissue NAD+. This decline is associated with ageing biology in laboratory studies, but is not proven to cause any specific human disease.
What is CD38’s role in NAD+?: CD38 is one of the major NAD+-consuming enzymes in the body, and it matters mostly for its sheer appetite for the molecule. Its expression and activity rise with age across tissues, so as CD38 climbs it draws down the available NAD+ pool — making increased CD38 activity one of the proposed drivers of the age-related NAD+ decline seen in older animals. CD38 also does more than consume NAD+: when it cleaves NAD+ and related molecules, it generates the calcium-mobilising second messengers cyclic ADP-ribose (cADPR) and NAADP. That ties the NAD+ pool directly into calcium signalling, one of the most universal control systems in the cell.
Does boosting NAD+ slow aging in humans?: The honest answer is that this is not established. The molecular biology is solid — NAD+ falls with age, and the enzymes that consume it sit at the centre of metabolic, DNA-repair, and calcium-signalling pathways. But almost all of the evidence that restoring NAD+ produces benefit comes from model organisms such as yeast, worms, flies, and mice, where raising NAD+ improves laboratory measures of healthspan. Those findings are the rationale for the human trials now underway, not a clinical result. NAD+ research is genuinely promising as a target, but that is a different statement from saying it slows ageing or treats any condition in people. NAD+ is a coenzyme, not a medicine, and this is not medical advice.